ANIXA BIOSCIENCES, INC. Interest Expense
ANIXA BIOSCIENCES, INC. (ANIX) reported Interest Expense of $7.27 thousand for the 3-month period ending 2020-07-31, per its 10-Q filed 2020-09-08.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2020-09-08
- ANIXA BIOSCIENCES, INC. interest expense for the quarter ending 2020-07-31 was $7.27K, a 60.43% decline year-over-year.
- ANIXA BIOSCIENCES, INC. interest expense for the quarter ending 2019-07-31 was $18.36K.
- ANIXA BIOSCIENCES, INC. interest expense for the quarter ending 2017-10-31 was $57.76K, a 57.75% decline year-over-year.
- ANIXA BIOSCIENCES, INC. interest expense for the quarter ending 2017-07-31 was $71.67K, a 45.85% decline year-over-year.
- ANIXA BIOSCIENCES, INC. interest expense for fiscal 2017 was $500.45K, a 3.75% decline from fiscal 2016.
- ANIXA BIOSCIENCES, INC. interest expense for fiscal 2016 was $519.95K, a 15.06% increase from fiscal 2015.
- ANIXA BIOSCIENCES, INC. interest expense for fiscal 2015 was $451.91K, a 64.24% decline from fiscal 2014.
- ANIXA BIOSCIENCES, INC. interest expense for fiscal 2014 was $1.26M, a 13.89% increase from fiscal 2013.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2020-07-31 | $7.27K 10-Q · filed 2020-09-08 | $32.71K 10-Q · filed 2020-09-08 | |||||
| 2019-07-31 | $18.36K 10-Q · filed 2020-09-08 | $53.78K 10-Q · filed 2020-09-08 | |||||
| 2017-10-31 | $57.76K derived: 10-K 12 month − 10-Q 9 month · filed 2019-01-11 | $129.43K derived: sum of 2 quarters · filed 2019-01-11 | $305.16K derived: sum of 3 quarters · filed 2019-01-11 | $500.45K 10-K · filed 2019-01-11 | |||
| 2017-07-31 | $71.67K 10-Q · filed 2018-09-07 | $247.39K derived: sum of 2 quarters · filed 2018-09-07 | $442.69K 10-Q · filed 2018-09-07 | $579.40K derived: sum of 4 quarters · filed 2018-09-07 | |||
| 2017-04-30 | $175.73K 10-Q · filed 2018-06-11 | $371.03K 10-Q · filed 2018-06-11 | $507.73K derived: sum of 3 quarters · filed 2018-06-11 | $640.09K derived: sum of 4 quarters · filed 2018-06-11 | |||
| 2017-01-31 | $195.30K 10-Q · filed 2018-03-09 | $332.01K derived: sum of 2 quarters · filed 2018-03-09 | $464.36K derived: sum of 3 quarters · filed 2018-03-09 | $591.34K derived: sum of 4 quarters · filed 2018-03-09 | |||
| 2016-10-31 | $136.71K derived: 10-K 12 month − 10-Q 9 month · filed 2018-01-09 | $269.06K derived: sum of 2 quarters · filed 2018-01-09 | $396.05K derived: sum of 3 quarters · filed 2018-01-09 | $519.95K 10-K · filed 2018-01-09 | |||
| 2016-07-31 | $132.36K 10-Q · filed 2017-09-08 | $259.34K derived: sum of 2 quarters · filed 2017-09-08 | $383.24K 10-Q · filed 2017-09-08 | $501.37K derived: sum of 4 quarters · filed 2017-09-08 | |||
| 2016-04-30 | $126.98K 10-Q · filed 2017-05-26 | $250.88K 10-Q · filed 2017-05-26 | $369.01K derived: sum of 3 quarters · filed 2017-05-26 | $484.99K derived: sum of 4 quarters · filed 2017-05-26 | |||
| 2016-01-31 | $123.90K 10-Q · filed 2017-03-16 | $242.03K derived: sum of 2 quarters · filed 2017-03-16 | $358.01K derived: sum of 3 quarters · filed 2017-03-16 | $466.62K derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-10-31 | $118.13K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-08 | $234.11K derived: sum of 2 quarters · filed 2016-12-08 | $342.72K derived: sum of 3 quarters · filed 2016-12-08 | $451.91K 10-K · filed 2016-12-08 | |||
| 2015-07-31 | $115.98K 10-Q · filed 2016-08-19 | $224.59K derived: sum of 2 quarters · filed 2016-08-19 | $333.78K 10-Q · filed 2016-08-19 | $515.36K derived: sum of 4 quarters · filed 2016-08-19 | |||
| 2015-04-30 | $108.61K 10-Q · filed 2016-05-20 | $217.80K 10-Q · filed 2016-05-20 | $399.37K derived: sum of 3 quarters · filed 2016-05-20 | $680.29K derived: sum of 4 quarters · filed 2016-05-20 | |||
| 2015-01-31 | $109.19K 10-Q · filed 2016-02-19 | $290.76K derived: sum of 2 quarters · filed 2016-02-19 | $571.67K derived: sum of 3 quarters · filed 2016-02-19 | $994.14K derived: sum of 4 quarters · filed 2016-02-19 | |||
| 2014-10-31 | $181.58K derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-23 | $462.49K derived: sum of 2 quarters · filed 2015-12-23 | $884.95K derived: sum of 3 quarters · filed 2015-12-23 | $1.26M 10-K · filed 2015-12-23 | |||
| 2014-07-31 | $280.91K 10-Q · filed 2015-08-18 | $703.38K derived: sum of 2 quarters · filed 2015-08-18 | $1.08M 10-Q · filed 2015-08-18 | $1.21M derived: sum of 4 quarters · filed 2015-08-18 | |||
| 2014-04-30 | $422.46K 10-Q · filed 2015-05-22 | $801.13K 10-Q · filed 2015-05-22 | $927.96K derived: sum of 3 quarters · filed 2015-05-22 | $1.05M derived: sum of 4 quarters · filed 2015-05-22 | |||
| 2014-01-31 | $378.67K 10-Q · filed 2015-03-09 | $505.50K derived: sum of 2 quarters · filed 2015-03-09 | $630.53K derived: sum of 3 quarters · filed 2015-03-09 | $1.47M derived: sum of 4 quarters · filed 2015-03-09 | |||
| 2013-10-31 | $126.83K derived: 10-K 12 month − 10-Q 9 month · filed 2015-01-29 | $251.87K derived: sum of 2 quarters · filed 2015-01-29 | $1.09M derived: sum of 3 quarters · filed 2015-01-29 | $1.11M 10-K · filed 2015-01-29 | |||
| 2013-07-31 | $125.03K 10-Q · filed 2014-09-15 | -$125.03K 10-Q/A · filed 2013-09-20 | $960.49K derived: sum of 2 quarters · filed 2014-09-15 | $982.69K 10-Q · filed 2014-09-15 | -$982.69K 10-Q/A · filed 2013-09-20 | ||
| 2013-04-30 | $835.46K 10-Q · filed 2014-06-16 | -$835.46K 10-Q/A · filed 2013-06-19 | $857.65K 10-Q · filed 2014-06-16 | -$857.65K 10-Q/A · filed 2013-06-19 | |||
| 2013-01-31 | $22.20K 10-Q · filed 2014-03-17 | ||||||
| 2012-10-31 | $7.66K 10-K/A · filed 2014-01-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |